• Clinigen entered an exclusive commercialization and distribution partnership with ShanZeBIO for Avelox (moxifloxacin) across 16 markets.
• Deal targets territories spanning Asia-Pacific, the Middle East, Africa, Europe, supporting continued product availability through established commercial channels.
• Clinigen will run commercialization, distribution, regulatory affairs, supply chain management, commercial operations across the agreed markets.
• ShanZeBIO will supply the product, provide pharmaceutical expertise to support rollout, supply planning, distribution execution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinigen Ltd. published the original content used to generate this news brief on September 23, 2026, and is solely responsible for the information contained therein.